HOME ABOUT US ADVERTISE SUBSCRIBE SITE MAP HELP CONTACT BIOTECH WORK FOR US  
Saturday
10 May 2008
Make BTN my HomePage 
 






LAST WEEK'S STORIES

 Thursday, 8 May 2008

Capital raising a boost for biotech: Experts
(Thursday, 8 May 2008)

THE news that Phosphagenics has completed a $9.1 million capital raising is a shot in the arm for the whole biotechnology industry, according to industry analysts.
Full Story...



OvPlex finds the mark
(Thursday, 8 May 2008)

HEALTHLINX and ARL Pathology will begin the marketing and mass distribution of OvPlex, their new ovarian cancer biomarkers, in the third quarter of 2008. Using a simple blood test the companies say the product is the most accurate ovarian cancer diagnostic on the market.
Full Story...



Merck wins worst news week award
(Thursday, 8 May 2008)

GLOBAL pharmaceutical company Merck has had a stunning run of bad news in recent weeks earning it a silver medal from analysts for the worst news week.
Full Story...



Prana’s Parkinson’s drug shows benefit
(Thursday, 8 May 2008)

BIOPHARMACEUTICAL company Prana has identified novel therapeutic drug candidates in its Parkinson’s disease program which is attempting to target the underlying cause of the Parkinson’s disease.
Full Story...



Ventracor clinical trials gain momentum
(Thursday, 8 May 2008)

GLOBAL medical device company Ventracor on Tuesday announced the reaching of a milestone, with 250 patients now having been implanted with its VentrAssist left ventricular assist device (LVAD).
Full Story...



Antisense begins preclinical studies of ATL1103
(Thursday, 8 May 2008)

AUSTRALIAN biopharmaceutical company Antisense Therapeutics has announced that formal preclinical toxicology studies of its growth and sight disorders drug ATL1103 have begun in North America.
Full Story...



Clinical Cell Culture rebadged
(Thursday, 8 May 2008)

CLINICAL Cell Culture has announced that it proposes to change the company’s name to Avita Medical Limited and to undertake a one-for-10 share consolidation.
Full Story...



Bio People: Xceed Capital, Apollo Life Sciences, Life Therapeutics, IBA
(Thursday, 8 May 2008)

XCEED Capital has announced the appointment of Dr Stewart Washer as an executive director of the company. The company says Washer has plenty of experience in the biotechnology and commercialisation spheres, and was one of the founders of Phylogica.
Full Story...


 Wednesday, 7 May 2008

Sunshine plans capital raising
(Wednesday, 7 May 2008)

CARDIAC device company Sunshine Heart plans to raise $A5.4 million through a non-renounceable rights issue of 77.8 million shares to support the proposed US clinical trial of its next generation, fully implantable C-Pulse device.
Full Story...



QRxPharma feeling no pain
(Wednesday, 7 May 2008)

Q8003IR has done all the things QRxPharma wanted. The dual-opioid analgesic has successfully met Phase 3 trial end points with significant reductions in post-operative pain and looks good for a 2010 launch, the company says.
Full Story...



HeartWare to start pumping cash
(Wednesday, 7 May 2008)

HEARTWARE will immediately commence a US bridge-to-transplant clinical trial of its left ventricular assist system following conditional investigational device exemption approval from the US Food and Drug Administration.
Full Story...



First implant of CardioCel biomaterial patches a success
(Wednesday, 7 May 2008)

PERTH-based biotechnology company bioMD has announced that the first human implant of its CardioCel bioimplant tissue patches has successfully taken place in South Africa as part of a Phase 2 trial.
Full Story...



Bronchitol to get second trial: Pharmaxis
(Wednesday, 7 May 2008)

PHARMAXIS has confirmed it will undertake a second Phase 3 trial of the company’s bronchiectasis treatment, Bronchitol, after last month revealing European regulatory authorities were likely to insist on the mucus clearing agent’s second trial.
Full Story...



Ellex fails to meet expectations
(Wednesday, 7 May 2008)

ELLEX Medical Lasers, a designer and manufacturer of ophthalmic laser and ultrasound systems, has announced that due to the difficult economic environment, sales growth and pre-tax earnings for the 2008 financial year are not expected to be as strong as previously advised.
Full Story...



ResMed announces financial results
(Wednesday, 7 May 2008)

MAJOR Australian sleep medicine company ResMed on Friday announced its revenue and income results for the quarter and nine months ended March 31, 2008.
Full Story...



OptiScan begins European multi-centre trial
(Wednesday, 7 May 2008)

THE European multi-centre trial of the OptiScan endomicroscope has begun and will draw 200 cases from hospitals in Germany, Italy and England. It is scheduled for completion in early 2009.
Full Story...


 Monday, 5 May 2008

Market Pulse: Biotech future improving
(Monday, 5 May 2008)

THE winds of the biotech sector appear to be changing for the better with some positive revaluations of biotechnology stocks expected. Novogen shares performed strongly with the industry eagerly awaiting the outcome of its Phenoxodiol (ovation) trial, while ImpediMed’s positive data supporting its lymphoedema device has also struck a chord with investors.
Full Story...




Click here to read today's news stories.